List of Excipients in Branded Drug CLARITHROMYCIN

Generic Drugs Containing CLARITHROMYCIN

Company	Ingredient	NDC	Excipient
Lannett Company Inc	clarithromycin	0527-1930	GLYCERYL DIBEHENATE
Lannett Company Inc	clarithromycin	0527-1930	HYPROMELLOSES
Lannett Company Inc	clarithromycin	0527-1930	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in CLARITHROMYCIN?

# Of NDCs	Excipient
2	ALUMINUM OXIDE
1	ANHYDROUS CITRIC ACID
76	CELLULOSE, MICROCRYSTALLINE

Clarithromycin Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

Clarithromycin is a mature macrolide with extensive generic competition, limited active-patent protection, and established oral dosage forms. Commercial opportunity depends on formulation execution rather than basic active-ingredient exclusivity. The strongest opportunities are pediatric taste masking, stable oral suspensions, modified-release tablets, differentiated combination products, and reliable supply of regulatory-compliant excipients.

What is the current commercial position of clarithromycin?

Clarithromycin is a semisynthetic macrolide antibiotic marketed for respiratory tract infections, skin and soft-tissue infections, Helicobacter pylori eradication, and selected mycobacterial infections. It is available as immediate-release tablets, extended-release tablets, oral granules for suspension, and, in some markets, injectable products.

The reference product is Biaxin, developed by Abbott Laboratories. The active ingredient is now widely available from generic manufacturers in the United States, Europe, Asia, and emerging markets.

Product characteristic	Commercial status
Active ingredient	Clarithromycin
Therapeutic class	Macrolide antibacterial
Reference brand	Biaxin and Biaxin XL
Main oral forms	Immediate-release tablets, extended-release tablets, oral suspension
Pediatric use	Oral suspension and tablet formulations, subject to age and indication
Generic status	Broadly available
U.S. FDA pathway	Abbreviated New Drug Application, or ANDA, for most generic products
Core composition-of-matter protection	Expired
Main differentiation route	Formulation, taste, stability, packaging, supply, and combination products

Clarithromycin has important safety and interaction limitations. It is a strong CYP3A4 inhibitor, can prolong the QT interval, and has clinically relevant interactions with statins, anticoagulants, antiarrhythmics, and other medicines. These characteristics affect product labeling, clinical positioning, and the commercial value of new formulations.

When did clarithromycin lose exclusivity?

Clarithromycin lost practical market exclusivity many years ago. The original Biaxin approval occurred in 1991, and generic clarithromycin entered after expiration of the relevant patents and regulatory exclusivities.

The extended-release Biaxin XL product was approved later, but its formulation and related patent protection also no longer provide meaningful market exclusivity for the active ingredient. Generic immediate-release and extended-release products are commercially available.

What is the FDA regulatory status of clarithromycin?

The FDA has approved clarithromycin products through several new drug applications and generic ANDAs. The regulatory record includes:

• Immediate-release tablets
• Extended-release tablets
• Granules for oral suspension
• Products for adult and pediatric populations
• Products used in H. pylori eradication regimens
• Products used for Mycobacterium avium complex treatment or prophylaxis in defined populations

The FDA labeling identifies contraindications and warnings related to QT prolongation, drug interactions, hepatic injury, and coadministration with certain medicines. A new formulation must preserve relevant exposure characteristics and maintain clear labeling for these risks. [1]

What patents protect clarithromycin?

The principal chemical and product patents associated with clarithromycin are expired. The commercial patent question is therefore formulation-specific rather than molecule-specific.

How many patents cover clarithromycin?

The number of historical patents is substantially larger than the number of patents with current commercial blocking power. Patent families have covered:

• Clarithromycin composition and chemical preparation
• Crystalline or solid-state forms
• Extended-release matrices
• Granules and suspension systems
• Taste-masked dosage forms
• Combination therapies
• Manufacturing processes

The FDA Orange Book should be checked for the specific reference product and dosage form because listed patents can differ by product and may include method-of-use or formulation claims. An Orange Book listing does not establish that a patent remains enforceable or that it will block a particular generic product. [2]

What generic entry risks exist for clarithromycin?

Generic entry risk is high for conventional immediate-release tablets and oral suspensions. The risk is lower for products that require:

• A technically robust extended-release profile
• Strong taste masking
• Long-term suspension stability
• Specialized multiparticulate manufacturing
• Difficult-to-source excipients
• Combination-product development
• Country-specific pediatric or hospital tenders

The absence of molecule-level exclusivity shifts value toward manufacturing know-how, regulatory execution, quality systems, and customer contracts.

Which clarithromycin formulations offer the best excipient opportunities?

The most commercially relevant excipient strategies are dosage-form specific.

Dosage form	Main formulation problem	High-value excipient functions	Commercial opportunity
Immediate-release tablet	Dissolution, hardness, manufacturability	Binder, disintegrant, lubricant, glidant	Low-cost, high-volume generic supply
Extended-release tablet	Controlled release and dose dumping prevention	Hydrophilic matrix polymer, insoluble polymer, pore former	Moderate technical barrier
Oral suspension	Bitter taste, sedimentation, chemical stability	Sweetener, flavor, suspending agent, buffer, preservative	Strong pediatric differentiation
Dry granules	Reconstitution, flow, stability	Granulation binder, suspending system, wetting agent	Regional and pediatric opportunity
Film-coated tablet	Odor, appearance, swallowability	Film former, plasticizer, pigment, opacifier	Incremental patient acceptability
Multiparticulate system	Taste masking and release control	Polymer coating, anti-tacking agent, cushioning excipient	Higher technical barrier
Intravenous product	Solubility, compatibility, sterility	pH modifier, cosolvent, tonicity agent	Limited commercial scope and higher regulatory burden

What excipients are suitable for immediate-release clarithromycin tablets?

Immediate-release tablets require a formulation that produces rapid and reproducible dissolution despite clarithromycin’s hydrophobicity and relatively low aqueous solubility.

Typical excipient categories include:

• Microcrystalline cellulose or dibasic calcium phosphate as a diluent
• Povidone or copovidone as a binder
• Croscarmellose sodium, crospovidone, or sodium starch glycolate as a superdisintegrant
• Colloidal silicon dioxide as a glidant
• Magnesium stearate or sodium stearyl fumarate as a lubricant
• Hypromellose-based coating systems for appearance and swallowability

The formulation target is not simply rapid disintegration. The developer must demonstrate consistent dissolution across commercial-scale batches and manage the effect of lubricant concentration, compression force, particle size, and moisture.

For a generic tablet, excipient selection should support a low-cost direct-compression or dry-granulation process. Wet granulation may improve uniformity but can increase development time and moisture-related risk.

How can an immediate-release tablet be differentiated?

Differentiation options include:

• Smaller tablet size at the same dose
• Improved swallowability
• Reduced odor
• Color coding by strength
• Unit-dose blister packaging
• Scored tablets where permitted
• Lower-cost manufacturing with equivalent performance
• Supply continuity for hospital and government tenders

These attributes generally do not create strong patent barriers. Their value is commercial and operational.

What excipients are suitable for clarithromycin oral suspension?

Oral suspension is the most attractive excipient-led segment because clarithromycin is intensely bitter and pediatric administration is difficult without effective taste masking.

A commercial suspension typically needs four performance attributes:

1. Acceptable taste after reconstitution
2. Uniform dose delivery after shaking
3. Adequate chemical and physical stability
4. Easy reconstitution and pourability

Relevant excipient categories include:

Function	Candidate excipient classes
Sweetening	Sucrose, sorbitol, sucralose, saccharin, aspartame where appropriate
Flavoring	Fruit flavors, berry systems, citrus systems
Suspending	Xanthan gum, hypromellose, microcrystalline cellulose-carboxymethylcellulose systems
Wetting	Polysorbates or other suitable surfactants
Buffering	Citrate or phosphate systems, subject to stability and compatibility
Preserving	Parabens, sodium benzoate, or other permitted systems
Antifoaming	Silicone-based or other approved antifoaming systems
Bulking and texture	Sugars, polyols, and structured suspending systems

The formulation should avoid excessive viscosity. A suspension that is physically stable but difficult to pour or administer can fail in routine pediatric use.

How should clarithromycin bitterness be masked?

Taste-masking approaches include:

• Polymer coating of drug particles
• Ion-exchange resin complexes
• Adsorption onto porous carriers
• Lipid or wax barriers
• pH-mediated reduction in dissolved drug during oral residence
• Flavor and sweetener systems
• Multiparticulate granules dispersed in a palatable vehicle

A simple flavor change is unlikely to solve clarithromycin’s bitterness. The strongest strategy is to reduce free drug concentration in the mouth while preserving rapid release after swallowing.

Taste masking must be evaluated using human sensory testing or a validated surrogate method, together with dissolution testing across relevant pH conditions. Excessive coating can delay release or create bioavailability differences.

What excipients are suitable for extended-release clarithromycin?

Extended-release clarithromycin products use matrix or multiparticulate release systems. The formulation objective is to produce a controlled plasma profile while maintaining acceptable bioavailability and avoiding dose dumping.

Potential excipient classes include:

• Hypromellose of controlled viscosity grades
• Polyethylene oxide
• Ethylcellulose
• Methacrylate copolymers
• Polyvinyl acetate-based matrix systems
• Lactose, mannitol, or other soluble pore-forming diluents
• Hydrophobic lubricants and release-modifying materials

The main development risks are:

• Food effects
• Alcohol-induced release acceleration
• Tablet size
• Dose dumping
• Variable gastric residence
• Scale-up sensitivity
• Multiparticulate coating uniformity

Extended-release products have higher development costs than immediate-release tablets because in vitro dissolution may not fully predict in vivo performance. A successful product needs a robust dissolution method, a defensible bioequivalence strategy, and strong control of critical material attributes.

What manufacturing and IP barriers affect clarithromycin products?

Clarithromycin itself is manufactured by chemical modification of erythromycin A. The active pharmaceutical ingredient is available from multiple international suppliers, but commercial quality depends on impurity control, polymorphic behavior, residual solvents, and microbiological standards.

What manufacturing barriers are commercially relevant?

Key barriers include:

• Consistent particle-size distribution
• Low impurity and degradation-product levels
• Reliable flow and compressibility
• Control of polymorphic or solid-state variation
• Suspension reconstitution performance
• Uniform coating of taste-masked particles
• Reproducible extended-release dissolution
• Stability under high-temperature and high-humidity conditions

Excipient supply can create a greater commercial barrier than patent protection. A formulation dependent on a single grade of high-viscosity polymer, specialized coating material, or pediatric flavor system may face shortages, qualification delays, or regional registration problems.

Does clarithromycin have meaningful formulation patent risk?

The risk is product-specific. Old formulation patents may be expired, abandoned, invalidated, or irrelevant to a proposed generic design. New patent filings may still attempt to protect:

• Narrow release profiles
• Specific excipient ratios
• Taste-masked particles
• Pediatric compositions
• Stable suspension systems
• Combination products
• Manufacturing parameters

A formulation patent has commercial value only if its claims cover a commercially necessary feature and can withstand validity and infringement challenges. Freedom-to-operate analysis should focus on active claims in each target jurisdiction.

Which companies are challenging clarithromycin exclusivity?

Clarithromycin is already subject to broad generic competition. Major generic and contract-manufacturing participants have included companies such as Teva, Mylan, Sandoz, Dr. Reddy’s Laboratories, Lupin, Sun Pharmaceutical, Cipla, Torrent Pharmaceuticals, and regional manufacturers.

The competitive field varies by country because of:

• National marketing authorizations
• Local manufacturing requirements
• Tender access
• Reference-product rules
• Pricing controls
• Import restrictions
• Pediatric labeling requirements

For conventional tablets, competition is generally price-based. For oral suspension and modified-release products, competition shifts toward product quality, supply reliability, palatability, and regulatory documentation.

What patent litigation affects clarithromycin?

Clarithromycin’s major patent disputes are historical rather than central to current generic strategy. Earlier disputes involved Biaxin, Biaxin XL, chemical patents, formulation patents, and generic ANDA filings.

Current commercial diligence should examine:

• Whether any Orange Book-listed patent remains relevant
• Paragraph IV certifications filed for the target dosage form
• Any 30-month stay triggered by a qualifying patent suit
• Settlement agreements governing launch timing
• State or federal antitrust claims involving generic entry
• Pending patent applications covering new formulations

What is the Paragraph IV risk for clarithromycin?

Paragraph IV risk is low for standard immediate-release products because the principal market has been generic for years. It can be higher for a newly developed formulation that references an existing product but relies on a distinct release mechanism, taste-masking system, or combination.

A generic applicant challenging a listed patent under Paragraph IV must assess:

• Non-infringement
• Invalidity
• Unenforceability
• Regulatory exclusivity
• Product-specific patent listings
• Potential damages and launch-at-risk exposure

A patent settlement can delay entry even after a technical challenge is filed. The economic value of such a settlement is limited for an old molecule unless the formulation has meaningful commercial demand.

What licensing deals are available for clarithromycin?

Licensing opportunities are more likely to involve technology than the active ingredient. Relevant deal structures include:

• Pediatric taste-masking platforms
• Extended-release matrix technology
• Multiparticulate coating systems
• Ready-to-use suspension vehicles
• Regional distribution rights
• Contract manufacturing and supply agreements
• Fixed-dose H. pylori regimens
• Hospital and government tender supply

An active-ingredient license for standard clarithromycin tablets is unlikely to create substantial strategic value because multiple API suppliers and finished-dose manufacturers exist. A formulation license may be more valuable if it provides a measurable regulatory or commercial advantage.

How does clarithromycin compare with competing antibiotics?

Attribute	Clarithromycin	Azithromycin	Amoxicillin
Class	Macrolide	Macrolide	Penicillin
Pediatric liquid opportunity	High	High	High
Taste-masking burden	High	High	Moderate
CYP3A4 interaction risk	Significant	Lower	Low
QT concern	Significant	Present but generally lower interaction burden	Low
Generic competition	High	High	Very high
Modified-release opportunity	Established but limited	Limited	Limited
H. pylori role	Established component	Limited	Established component
Formulation differentiation	Suspension and release control	Suspension and dosing convenience	Stability and palatability

Clarithromycin’s commercial weakness is its interaction and resistance profile. Its commercial strength is its established clinical use, recognized regulatory history, and availability in multiple oral formats.

What is the revenue exposure for clarithromycin products?

Revenue exposure is concentrated in high-volume, low-margin generic channels:

• Retail prescriptions
• Pediatric suspensions
• H. pylori combination regimens
• Hospital tenders
• Emerging-market anti-infective portfolios
• Contract manufacturing

A conventional tablet strategy has limited pricing power. A differentiated pediatric suspension can support better retention and modest premium pricing if it improves acceptance, reduces preparation errors, or offers longer in-use stability.

A manufacturer should not assume that a technically superior excipient system will produce a premium. Payers and procurement agencies may treat the product as therapeutically interchangeable unless the difference is supported by labeling, patient-use data, adherence evidence, or supply advantages.

What is the best commercial excipient strategy for clarithromycin?

The strongest strategy is a tiered portfolio:

Tier 1: Low-cost immediate-release tablets

Use widely qualified excipients, simple manufacturing, and robust dissolution control. The objective is cost leadership and reliable supply.

Tier 2: Pediatric oral suspension

Invest in taste masking, suspension rheology, flavor stability, dosing-device compatibility, and high-temperature stability. This is the most defensible formulation-led opportunity.

Tier 3: Extended-release tablets

Pursue only where market demand supports the higher development and bioequivalence burden. Control food effects and dose-dumping risk from the start.

Tier 4: Combination and regimen products

Evaluate clarithromycin with amoxicillin, proton-pump inhibitors, or other H. pylori regimen components. The commercial opportunity depends on local treatment guidelines and the ability to secure a differentiated regulatory presentation.

Tier 5: Regional delivery formats

Consider sachets, dispersible systems, unit-dose suspensions, and ready-to-use products for markets with limited pharmacy compounding infrastructure.

Key Takeaways

• Clarithromycin is a mature, broadly generic macrolide with no meaningful molecule-level exclusivity.
• Immediate-release tablets are primarily a cost, quality, and supply-chain business.
• Pediatric suspension is the strongest excipient-led opportunity because clarithromycin is highly bitter.
• Taste masking must reduce oral drug exposure without impairing dissolution or bioavailability.
• Extended-release products have greater technical and regulatory barriers but limited market upside.
• Excipients should be selected for global regulatory acceptance, supply continuity, and scale-up robustness.
• Current patent risk is formulation-specific and should be assessed through Orange Book and jurisdictional freedom-to-operate review.
• Licensing value is concentrated in delivery technology, taste masking, manufacturing, and regional commercialization.
• Commercial success depends more on palatability, stability, procurement access, and reliable supply than on patent exclusivity.

FAQs About Clarithromycin Excipient Strategy

Can clarithromycin be formulated as a chewable tablet?

Yes. A chewable product requires effective taste masking, controlled mouthfeel, acceptable tablet texture, and rapid drug release. The bitterness of clarithromycin makes direct compression without a masking strategy commercially weak.

Which suspending agent is best for clarithromycin oral suspension?

Xanthan gum and microcrystalline cellulose-carboxymethylcellulose systems are common starting points. The best choice depends on sedimentation, redispersibility, viscosity, flavor compatibility, preservative performance, and stability after reconstitution.

Is sugar-free clarithromycin suspension commercially viable?

Yes. Sorbitol, sucralose, saccharin, and other sugar-reduction systems can support a sugar-free product. The formulation must control viscosity, osmolality, taste, dental considerations, and preservative performance.

Can clarithromycin be combined with a proton-pump inhibitor in one dosage form?

Technically, yes, but chemical and physical compatibility can be difficult. Acid-sensitive proton-pump inhibitors, moisture control, separate release requirements, and stability can make a co-pack more practical than a single fixed-dose dosage form.

Does a new clarithromycin excipient combination create patent protection?

It can, but only if the claims satisfy novelty, inventive-step or non-obviousness, written-description, and enablement standards. Broad claims covering routine excipient substitutions are vulnerable. Narrow claims tied to a demonstrated stability, taste, dissolution, or bioavailability advantage are more defensible.

References

1. U.S. Food and Drug Administration. (2023). Biaxin XL and clarithromycin prescribing information. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. U.S. Food and Drug Administration. (2019). ANDAs for certain highly soluble immediate release dosage forms. FDA.
4. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. ICH.
5. International Council for Harmonisation. (2019). Q8(R2): Pharmaceutical development. ICH.
6. DailyMed. (2024). Clarithromycin tablet, extended release; clarithromycin granules for oral suspension. National Library of Medicine.